ArticleProstate cancer and prostatic diseases2026
High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer.
Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: A systematic review and meta-analysis using contemporary consensus recommendations.Prostate cancer and prostatic diseases · 2026Review
- Coupled Cell-Intrinsic and Microenvironmental Heterogeneity Drives Divergent Trajectories in Castration-Resistant Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Intraprostatic steroid hormones and endocrine disruptors in prostate cancer.Endocrine-related cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe glucocorticoid receptor (GR) is a nuclear receptor protein for cortisol and other glucocorticoids and regulates the transcription of thousands of genes involved in metabolism, development, stress and inflammatory response. In prostate cancer, GR may confer resistance to anti-androgen receptor therapies by bypassing AR blockade. However, only few data are available on the prognostic role of GR expression in prostate cancer.
methodsTo estimate the prognostic value of GR, a tissue microarray containing 17,747 prostate cancers with associated follow-up and molecular data was analyzed by immunohistochemistry.
resultsAll patients had undergone radical prostatectomy. GR immunostaining was found in 10,832 (89.1%) of 12,125 interpretable tumors, including 48.5% with weak, 29.8% with moderate and 11% with strong staining intensity. Increased GR staining was strongly linked to adverse feature of the disease, including high tumor stage (pT), high classical and quantitative Gleason grade, presence of nodal metastases (pN+), a positive surgical margin (R1) status, and early biochemical recurrence (p < 0.0001 each). A multivariate analysis showed that the prognostic value of strong GR staining was independent of pT, Gleason grade, pN and R status. High level GR staining was significantly linked to TMPRSS2:ERG fusion (p < 0.0001) and high androgen receptor expression (p < 0.0001 each). A combined analysis of the impact of GR and AR on patient prognosis identified the best prognosis for AR
conclusionHigh level expression of GR is strongly linked to prostate cancer aggressiveness in uni- and multivariate analysis. GR immunohistochemistry - alone or in combination with other markers - holds great potential to identify patients with a high risk for tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.